Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CHINOOK THERAPEUTICS, INC.

(KDNY)
  Report
Real-time Estimate Cboe BZX  -  01:49:47 2023-02-07 pm EST
24.11 USD   -0.10%
02/06Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
01/11Transcript : Chinook Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 08:15 AM
CI
01/03Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wells Fargo Starts Chinook Therapeutics at Overweight With $30 Price Target

12/05/2022 | 08:24am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CHINOOK THERAPEUTICS, INC. 0.25% 24.14 Delayed Quote.-7.90%
WELLS FARGO & COMPANY -0.10% 47.62 Delayed Quote.15.48%
All news about CHINOOK THERAPEUTICS, INC.
02/06Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rul..
AQ
01/11Transcript : Chinook Therapeutics, Inc. Presents at 41st Annual J.P. Morgan H..
CI
01/03Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
AQ
2022Stifel Raises Price Target on Chinook Therapeutics to $43 From $30, Keeps Buy Rating
MT
2022Insider Sell: Chinook Therapeutics
MT
2022Wells Fargo Starts Chinook Therapeutics at Overweight With $30 Price Target
MT
2022Insider Sell: Chinook Therapeutics
MT
2022Insider Sell: Chinook Therapeutics
MT
2022Chinook Therapeutics to Present at Upcoming Investor Conferences
AQ
2022CHINOOK THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
More news
Analyst Recommendations on CHINOOK THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 5,76 M - -
Net income 2022 -178 M - -
Net cash 2022 349 M - -
P/E ratio 2022 -9,38x
Yield 2022 -
Capitalization 1 543 M 1 543 M -
EV / Sales 2022 207x
EV / Sales 2023 2 631x
Nbr of Employees -
Free-Float 97,4%
Chart CHINOOK THERAPEUTICS, INC.
Duration : Period :
Chinook Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHINOOK THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 24,13 $
Average target price 35,00 $
Spread / Average Target 45,0%
EPS Revisions
Managers and Directors
Eric L. Dobmeier Chairman, President & Chief Executive Officer
Eric Hands Claude Bjerkholt Chief Financial Officer
Andrew King Chief Scientific Officer
Tom Frohlich Chief Operating Officer
Srinivas Akkaraju Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CHINOOK THERAPEUTICS, INC.-7.90%1 543
REGENERON PHARMACEUTICALS, INC.8.54%83 397
VERTEX PHARMACEUTICALS4.24%78 258
WUXI APPTEC CO., LTD.12.89%39 435
BIONTECH SE-5.43%34 256
BEIGENE, LTD.11.48%25 531